Cytomark Ltd, as the owner of the IP and worldwide distribution rights for TransFix, is no longer operating and everything is now being transferred to Caltag Medsystems Ltd. Caltag is already the legal manufacturer of TransFix and now takes on …
Read MoreNews Feed
White Paper: Evaluation of TransFix/EDTA CSF Sample Storage Tubes compared to alternative preservation methods
Cytomark are pleased to announce the launch of their TransFix/EDTA CSF Sample Storage Tubes as CE marked in vitro diagnostic devices. Below we present finding on the effect of TransFix on cerebrospinal fluid samples, when compared to untreated samples, and …
Read MorePreservation of CD34+ Stem Cells and Precursors with TransFix
CD34+ population enumeration has multiple applications, for example to indicate whether a hematopoietic stem-cell harvest is ready to be performed for transplant, or to characterise progenitor/precursor populations such as B-cell precursors in Acute lymphoblastic leukaemia (ALL) samples. However, rare CD34+ …
Read MoreStabilisation of T-Cell Activation Markers
Measurement of T-cell activation can be important when assessing immune responses, however cells can become artificially activated over time once removed from the body. TransFix has been used to stabilise activated T-cell populations. We’ve presented a selection of publications to …
Read MoreStabilisation of Circulating Endothelial Progenitor Cells
TransFix stabilises lymphocytes for up to 14 days, but other cell populations have also been shown to be stable with TransFix. One example is Circulating Endothelial and Endothelial Progenitor Cells which have been referenced by multiple papers: TransFix for Delayed …
Read MoreTransFix Stabilisation of Blood Collected on Heparin Anticoagulants
Cytomark have validated TransFix for use with EDTA anticoagulant for lymphocyte phenotyping, however there are publications documenting the successful use of other anticoagulants such as heparin. Below are 2 examples of clinical trials where TransFix has been added to blood …
Read MorePreservation of mRNA from Isolated Circulating Tumour Cells
It is well documented that TransFix treated blood is compatible with isolation of circulating tumour cells, but new work published by Baird et al. describes a novel method of isolating CTCs, and the first published method of extracting mRNA from …
Read More
Innovative Applications of TransFix – March 2020
TransFix is designed for stabilisation of peripheral blood and cerebrospinal fluid to enumerate lymphocyte subpopulations by flow cytometry. However, researchers have developed many new and innovative uses of TransFix. We have highlighted publications showing the versatility of TransFix. Read on …
Read MoreStromal Vascular Fraction (SVF) Stabilisation
Applications of TransFix: Stabilisation of Adipose-derived Stromal Vascular Fraction (SVF) Independent research involving the use of TransFix to stabilise Adipose derived Stromal Vascular Fraction (SVF) for flow cytometry has been published. Stromal vascular fraction (SVF) from adipose tissue contains a …
Read MoreBronchoalveolar lavage fluid (BALF) Stabilisation
Applications of TransFix: Stabilisation of Bronchoalveolar lavage fluid (BALF) Independent research involving the use of TransFix to stabilise BALF samples has been published, including the use of TransFix for the enumeration of rat leucocytes present in BALF (case study 1). …
Read More